scispace - formally typeset
F

François Goldwasser

Researcher at University of Paris

Publications -  388
Citations -  15891

François Goldwasser is an academic researcher from University of Paris. The author has contributed to research in topics: Cancer & Sorafenib. The author has an hindex of 53, co-authored 357 publications receiving 12805 citations. Previous affiliations of François Goldwasser include French Institute of Health and Medical Research & Curie Institute.

Papers
More filters
Journal ArticleDOI

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Bertrand Routy, +76 more
- 05 Jan 2018 - 
TL;DR: It is found that primary resistance to ICIs can be attributed to abnormal gut microbiome composition, and Antibiotics inhibited the clinical benefit of ICIs in patients with advanced cancer.
Journal ArticleDOI

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

TL;DR: Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma and represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment.
Journal ArticleDOI

Prevalence of malnutrition and current use of nutrition support in patients with cancer.

TL;DR: The prevalence of malnutrition is high in patients with cancer, and systematic screening for and treatment ofnutrition is necessary.
Journal Article

Controlling Tumor Growth by Modulating Endogenous Production of Reactive Oxygen Species

TL;DR: In conclusion, antioxidant molecules may have opposite effects on tumor growth as SOD mimics can act in synergy with cytotoxic drugs to treat colon and liver cancers and reactive oxygen species can promote normal cellular proliferation and carcinogenesis.
Journal ArticleDOI

Management of hypertension in angiogenesis inhibitor-treated patients

TL;DR: No clear recommendation for an antihypertensive agent can be made in this context because there is a lack of controlled studies addressing the subject.